Blood Cancer Journal

Papers
(The H4-Index of Blood Cancer Journal is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort194
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M182
Disparities in time to treatment with oral antimyeloma medications158
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib122
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity115
Correction: Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells111
Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes108
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine107
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma100
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients95
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study84
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma81
Genomic landscape of hyperleukocytic acute myeloid leukemia75
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes75
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma74
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study74
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma73
In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study73
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor69
A multiparametric niche-like drug screening platform in acute myeloid leukemia63
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT62
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia61
Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report59
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid57
Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease52
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency51
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma49
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management49
Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia45
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression45
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study44
RSK1 dependency in FLT3-ITD acute myeloid leukemia43
CALRins5-mediated clonal hematopoiesis causes severe hemolytic anemia in a female PGK1Ser320Asn carrier43
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma43
Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma43
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma41
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome40
Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies39
Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute promyelocytic leukemia39
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis39
0.54817605018616